Ligase chain reaction with endonuclease IV correction and contamination control
AssigneeAbbott Laboratories
InventorsKeith C. Backman, John J. Carrino, George H. Shimer, Robert R. Yocum
Life of this patent
Estimating the term…
Loading patent…
AssigneeAbbott Laboratories
InventorsKeith C. Backman, John J. Carrino, George H. Shimer, Robert R. Yocum
Estimating the term…
The present invention involves methods of improving the Ligase Chain Reaction (LCR.TM.) amplification schemes by modifying at least one probe end so that the probability of the probe contributing to spurious ligation and signal development is greatly reduced. Only after specific hybridization of the modified probe with true target are the modified ends "corrected" by endonuclease IV in a target dependent fashion to allow participation of the probe in the enzymatic ligation reaction. Specific modifications include 3' phosphate blocking groups and nucleic acid overhangs containing an abasic site at the point of ligation. Further embodiments include probes modified to contain ribonucleotide moieties which, after amplification, can be cleaved by RNase to destroy the amplification products and reduce the risk of contamination.
In a ligase chain reaction method for amplifying a target nucleic acid sequence, said method including:
A diagnostic kit comprising in combination:
A nucleic acid probe having at least three deoxyribonucleotides covalently linked by phosphodiester linkages to define a probe having an available 3' position, the probe further comprising a ribonucleotide attached at the 3' position, the ribonucleotide having a further 3' position to which is attached a group of the formula:
Dependencies are inferred from the claim text.